Literature DB >> 31448651

The Associations of Neighborhood Availability of Marijuana Dispensaries and DATA-2000 Waivered Providers with Hospital Stays Related to Opioids.

Di Liang1, Yuyan Shi1.   

Abstract

Background: Evidence is emerging on how state-wide marijuana legalization and increased supply of DATA-2000 waivered providers may be associated with outcomes related to opioids. It is unknown whether such associations remain at the neighborhood level.
Objectives: This study examined the associations of neighborhood availability of marijuana dispensaries and DATA-2000 waivered providers with opioid-related hospital stays.
Methods: Discharge-level records of inpatient (N = 264,013) and observation stays (N = 12,621) were obtained from the Washington Comprehensive Hospital Abstract Reporting System from January through June 2016. Outcomes were indicators for inpatient stays related to opioid use disorder (OUD), inpatient stays related to opioid overdose, and observation stays related to OUD. Primary predictors were the density of marijuana dispensaries and DATA-2000 waivered providers at the zip code level. Multilevel logistic regressions with random intercepts were used to examine the cross-sectional associations, controlling for other patient and neighborhood characteristics.
Results: Patients living in neighborhoods with one more recreational marijuana dispensaries per square mile were more likely (OR = 1.54, p = .017) to be diagnosed with OUD in inpatient stays. Living in neighborhoods with increased density of medical marijuana dispensaries or DATA-2000 waivered providers was not associated with being diagnosed with OUD or opioid overdose in inpatient or observation stays. Conclusions: Recreational and medical marijuana dispensaries were differentially associated with opioid-related hospital stays. Further investigations are warranted to explore the causal pathways of the findings.

Entities:  

Keywords:  Marijuana dispensary; buprenorphine; hospitalization; marijuana; opioids

Mesh:

Substances:

Year:  2019        PMID: 31448651      PMCID: PMC6892428          DOI: 10.1080/10826084.2019.1650775

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  38 in total

Review 1.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

2.  Determinants of buprenorphine treatment for opioid dependence.

Authors:  Sean M Murphy; Paul A Fishman; Sterling McPherson; Dennis G Dyck; John R Roll
Journal:  J Subst Abuse Treat       Date:  2013-10-25

Review 3.  The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature.

Authors:  Gary M Reisfield; Ajay D Wasan; Robert N Jamison
Journal:  Pain Med       Date:  2009-09-29       Impact factor: 3.750

4.  Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Authors:  Roger A Rosenblatt; C Holly A Andrilla; Mary Catlin; Eric H Larson
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

5.  The availability of medical marijuana dispensary and adolescent marijuana use.

Authors:  Yuyan Shi
Journal:  Prev Med       Date:  2016-07-25       Impact factor: 4.018

6.  Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States.

Authors:  Mark Olfson; Melanie M Wall; Shang-Min Liu; Carlos Blanco
Journal:  Am J Psychiatry       Date:  2017-09-26       Impact factor: 18.112

Review 7.  Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

Authors:  Kevin P Hill
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

8.  Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014.

Authors:  Di Liang; Yuhua Bao; Mark Wallace; Igor Grant; Yuyan Shi
Journal:  Addiction       Date:  2018-08-06       Impact factor: 6.526

Review 9.  Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.

Authors:  Mary E Lynch; Fiona Campbell
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

10.  Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs.

Authors:  Wayne D Hall; Michael Lynskey
Journal:  Drug Alcohol Rev       Date:  2005-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.